{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T01:37:50Z","timestamp":1789004270061,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Therapeutic plasma exchange (TPE) is an extracorporeal technique where patient\u2019s plasma containing pathogenic substances is separated and removed from the whole blood, while the cellular component is returned to the patient mixed with replacement solution via an apheresis machine. Due to its ability to remove pathogenic substances from plasma including immunoglobulins, TPE has proven efficacious in the management of various disorders across different medical disciplines, including plasma cell dyscrasias, which are characterized by the abundant secretion of non-functional immunoglobulins produced by an abnormally proliferating plasma cell clone. This review summarizes the current indications of TPE in plasma cell-related disorders and discusses its application, safety, and therapeutic effects.<\/jats:p>","DOI":"10.1007\/s00277-024-05712-0","type":"journal-article","created":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T09:12:10Z","timestamp":1711962730000},"page":"3941-3946","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The role of therapeutic plasma exchange in plasma cell disorders"],"prefix":"10.1007","volume":"103","author":[{"given":"Danai","family":"Dima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Khouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,1]]},"reference":[{"issue":"3","key":"5712_CR1","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.transci.2019.04.007","volume":"58","author":"M Fern\u00e1ndez-Zarzoso","year":"2019","unstructured":"Fern\u00e1ndez-Zarzoso M, G\u00f3mez-Segu\u00ed I, de la Rubia J (2019) Therapeutic plasma exchange: review of current indications. Transfus Apher Sci 58(3):247\u2013253","journal-title":"Transfus Apher Sci"},{"key":"5712_CR2","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2147\/CMAR.S340472","volume":"14","author":"Y Hu","year":"2022","unstructured":"Hu Y, Yang H, Fu S, Wu J (2022) Therapeutic plasma exchange: for Cancer patients. Cancer Manag Res 14:411\u2013425","journal-title":"Cancer Manag Res"},{"key":"5712_CR3","unstructured":"The Immunomodulatory Role of Therapeutic Plasma Exchange in Peripheral Nervous System and Neuromuscular Diseases. 1 [Internet]. 2017 Feb 2 [cited 2024 Feb 10]; Available from: https:\/\/touchneurology.com\/neuromuscular-diseases\/journal-articles\/the-immunomodulatory-role-of-therapeutic-plasma-exchange-in-peripheral-nervous-system-and-neuromuscular-diseases\/"},{"issue":"20","key":"5712_CR4","first-page":"2946","volume":"268","author":"B Barlogie","year":"1992","unstructured":"Barlogie B, Alexanian R, Jagannath S (1992) Plasma Cell Dyscrasias JAMA 268(20):2946\u20132951","journal-title":"Plasma Cell Dyscrasias JAMA"},{"key":"5712_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/asheducation.V2012.1.7.3797920","volume":"2012","author":"JL Winters","year":"2012","unstructured":"Winters JL (2012) Plasma exchange: concepts, mechanisms, and an overview of the American Society for Apheresis guidelines. Hematol Am Soc Hematol Educ Program 2012:7\u201312","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"3","key":"5712_CR6","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/bjh.12629","volume":"164","author":"HM Reeves","year":"2014","unstructured":"Reeves HM, Winters JL (2014) The mechanisms of action of plasma exchange. Br J Haematol 164(3):342\u2013351","journal-title":"Br J Haematol"},{"issue":"1","key":"5712_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70(1):7\u201330","journal-title":"CA Cancer J Clin"},{"issue":"17","key":"5712_CR8","doi-asserted-by":"publisher","first-page":"4082","DOI":"10.3390\/cancers14174082","volume":"14","author":"D Dima","year":"2022","unstructured":"Dima D, Jiang D, Singh DJ, Hasipek M, Shah HS, Ullah F et al (2022) Multiple myeloma therapy: emerging trends and challenges. Cancers (Basel) 14(17):4082","journal-title":"Cancers (Basel)"},{"issue":"4","key":"5712_CR9","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1081\/JDI-100100888","volume":"22","author":"V Sakhuja","year":"2000","unstructured":"Sakhuja V, Jha V, Varma S, Joshi K, Gupta KL, Sud K et al (2000) Renal involvement in multiple myeloma: a 10-year study. Ren Fail 22(4):465\u2013477","journal-title":"Ren Fail"},{"issue":"12","key":"5712_CR10","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538\u2013548","journal-title":"Lancet Oncol"},{"issue":"3","key":"5712_CR11","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S1092-9134(00)90042-X","volume":"4","author":"GA Herrera","year":"2000","unstructured":"Herrera GA (2000) Renal manifestations of plasma cell dyscrasias: an appraisal from the patients\u2019 bedside to the research laboratory. Ann Diagn Pathol 4(3):174\u2013200","journal-title":"Ann Diagn Pathol"},{"issue":"1","key":"5712_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-023-00806-w","volume":"13","author":"N Leung","year":"2023","unstructured":"Leung N, Rajkumar SV (2023) Multiple myeloma with acute light chain cast nephropathy. Blood Cancer J 13(1):1\u20137","journal-title":"Blood Cancer J"},{"issue":"21","key":"5712_CR13","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1182\/blood.2019003807","volume":"135","author":"V Royal","year":"2020","unstructured":"Royal V, Leung N, Troyanov S, Nasr SH, \u00c9coti\u00e8re L, LeBlanc R et al (2020) Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study. Blood 135(21):1833\u20131846","journal-title":"Blood"},{"issue":"1","key":"5712_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nrneph.2011.168","volume":"8","author":"CA Hutchison","year":"2011","unstructured":"Hutchison CA, Batuman V, Behrens J, Bridoux F, Sirac C, Dispenzieri A et al (2011) The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nat Rev Nephrol 8(1):43\u201351","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"5712_CR15","first-page":"484","volume":"124","author":"PW Sanders","year":"1994","unstructured":"Sanders PW (1994) Pathogenesis and treatment of myeloma kidney. J Lab Clin Med 124(4):484\u2013488","journal-title":"J Lab Clin Med"},{"issue":"4","key":"5712_CR16","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrneph.2012.14","volume":"8","author":"CA Hutchison","year":"2012","unstructured":"Hutchison CA, Blad\u00e9 J, Cockwell P, Cook M, Drayson M, Fermand JP et al (2012) Novel approaches for reducing free light chains in patients with myeloma kidney. Nat Rev Nephrol 8(4):234\u2013243","journal-title":"Nat Rev Nephrol"},{"issue":"7","key":"5712_CR17","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.1016\/S1470-2045(23)00223-1","volume":"24","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA, Merlini G, Bridoux F, Leung N, Mikhael J, Harrison SJ et al (2023) Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group. Lancet Oncol 24(7):e293\u2013311","journal-title":"Lancet Oncol"},{"issue":"13","key":"5712_CR18","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","volume":"34","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E et al (2016) International Myeloma Working Group Recommendations for the diagnosis and management of Myeloma-related renal impairment. J Clin Oncol 34(13):1544\u20131557","journal-title":"J Clin Oncol"},{"issue":"6","key":"5712_CR19","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1681\/ASN.2010080857","volume":"22","author":"CA Hutchison","year":"2011","unstructured":"Hutchison CA, Cockwell P, Stringer S, Bradwell A, Cook M, Gertz MA et al (2011) Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol 22(6):1129\u20131136","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"5712_CR20","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/ajh.24335","volume":"91","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Roussou M, Gavriatopoulou M, Psimenou E, Eleutherakis-Papaiakovou E, Migkou M et al (2016) Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis. Am J Hematol 91(5):499\u2013502","journal-title":"Am J Hematol"},{"issue":"24","key":"5712_CR21","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1056\/NEJMc1101834","volume":"364","author":"BL Burnette","year":"2011","unstructured":"Burnette BL, Leung N, Rajkumar SV (2011) Renal improvement in myeloma with bortezomib plus plasma exchange. N Engl J Med 364(24):2365\u20132366","journal-title":"N Engl J Med"},{"issue":"23","key":"5712_CR22","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1200\/JCO.20.00298","volume":"38","author":"F Bridoux","year":"2020","unstructured":"Bridoux F, Arnulf B, Karlin L, Blin N, Rabot N, Macro M et al (2020) Randomized trial comparing double Versus Triple Bortezomib-based regimen in patients with multiple myeloma and acute kidney Injury due to cast Nephropathy. J Clin Oncol 38(23):2647\u20132657","journal-title":"J Clin Oncol"},{"issue":"11","key":"5712_CR23","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1002\/ajh.25959","volume":"95","author":"AG Szabo","year":"2020","unstructured":"Szabo AG, Thorsen J, Iversen KF, Hansen CT, Teodorescu EM, Pedersen SB et al (2020) Clinically-suspected cast nephropathy: a retrospective, national, real-world study. Am J Hematol 95(11):1352\u20131360","journal-title":"Am J Hematol"},{"issue":"12","key":"5712_CR24","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1111\/nep.12979","volume":"22","author":"J Sethi","year":"2017","unstructured":"Sethi J, Ramachandran R, Malhotra P, Nada R, Pinnamaneni V, Kumar V et al (2017) Plasma exchange in the management of new onset multiple myeloma with cast nephropathy treated with bortezomib based chemotherapy. Nephrol (Carlton) 22(12):1035\u20131036","journal-title":"Nephrol (Carlton)"},{"issue":"11","key":"5712_CR25","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1038\/ki.2008.108","volume":"73","author":"N Leung","year":"2008","unstructured":"Leung N, Gertz MA, Zeldenrust SR, Rajkumar SV, Dispenzieri A, Fervenza FC et al (2008) Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int 73(11):1282\u20131288","journal-title":"Kidney Int"},{"issue":"1","key":"5712_CR26","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/1744-9987.12606","volume":"22","author":"V Premuzic","year":"2018","unstructured":"Premuzic V, Batinic J, Roncevic P, Basic-Jukic N, Nemet D, Jelakovic B (2018) Role of Plasmapheresis in the management of Acute kidney Injury in patients with multiple myeloma: should we abandon it? Ther Apher Dial 22(1):79\u201386","journal-title":"Ther Apher Dial"},{"issue":"2","key":"5712_CR27","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s13730-021-00668-w","volume":"11","author":"S Mizuno","year":"2022","unstructured":"Mizuno S, Kitayama C, Mashiko S, Sanada S (2022) Renal recovery following daratumumab, lenalidomide, and dexamethasone therapy in a patient with newly diagnosed dialysis-dependent multiple myeloma. CEN Case Rep 11(2):265\u2013268","journal-title":"CEN Case Rep"},{"issue":"4","key":"5712_CR28","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/archinte.1990.00390160111022","volume":"150","author":"WJ Johnson","year":"1990","unstructured":"Johnson WJ, Kyle RA, Pineda AA, O\u2019Brien PC, Holley KE (1990) Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med 150(4):863\u2013869","journal-title":"Arch Intern Med"},{"issue":"6","key":"5712_CR29","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1038\/ki.1988.127","volume":"33","author":"P Zucchelli","year":"1988","unstructured":"Zucchelli P, Pasquali S, Cagnoli L, Ferrari G (1988) Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int 33(6):1175\u20131180","journal-title":"Kidney Int"},{"issue":"11","key":"5712_CR30","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/0003-4819-143-11-200512060-00005","volume":"143","author":"WF Clark","year":"2005","unstructured":"Clark WF, Stewart AK, Rock GA, Sternbach M, Sutton DM, Barrett BJ et al (2005) Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med 143(11):777\u2013784","journal-title":"Ann Intern Med"},{"issue":"5","key":"5712_CR31","doi-asserted-by":"publisher","first-page":"391","DOI":"10.5414\/CP202245","volume":"53","author":"X Yu","year":"2015","unstructured":"Yu X, Gan L, Wang Z, Dong B, Chen X (2015) Chemotherapy with or without plasmapheresis in acute renal failure due to multiple myeloma: a meta-analysis. Int J Clin Pharmacol Ther 53(5):391\u2013397","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"3","key":"5712_CR32","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/jca.21705","volume":"34","author":"A Padmanabhan","year":"2019","unstructured":"Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E et al (2019) Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based Approach from the Writing Committee of the American Society for Apheresis: the Eighth Special Issue. J Clin Apher 34(3):171\u2013354","journal-title":"J Clin Apher"},{"issue":"3","key":"5712_CR33","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1182\/blood-2016-09-719773","volume":"129","author":"E Muchtar","year":"2017","unstructured":"Muchtar E, Magen H, Gertz MA (2017) How I treat cryoglobulinemia. Blood 129(3):289\u2013298","journal-title":"Blood"},{"issue":"7","key":"5712_CR34","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/ajh.24745","volume":"92","author":"S Sidana","year":"2017","unstructured":"Sidana S, Rajkumar SV, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK et al (2017) Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. Am J Hematol 92(7):668\u2013673","journal-title":"Am J Hematol"},{"issue":"2","key":"5712_CR35","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/ajh.23608","volume":"89","author":"A N\u00e9el","year":"2014","unstructured":"N\u00e9el A, Perrin F, Decaux O, Dejoie T, Tessoulin B, Halliez M et al (2014) Long-term outcome of monoclonal (type 1) cryoglobulinemia. Am J Hematol 89(2):156\u2013161","journal-title":"Am J Hematol"},{"issue":"5","key":"5712_CR36","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1111\/bjh.13196","volume":"168","author":"S Harel","year":"2015","unstructured":"Harel S, Mohr M, Jahn I, Aucouturier F, Galicier L, Asli B et al (2015) Clinico-biological characteristics and treatment of type I monoclonal cryoglobulinaemia: a study of 64 cases. Br J Haematol 168(5):671\u2013678","journal-title":"Br J Haematol"},{"issue":"2","key":"5712_CR37","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/MD.0b013e318288925c","volume":"92","author":"B Terrier","year":"2013","unstructured":"Terrier B, Karras A, Kahn JE, Le Guenno G, Marie I, Benarous L et al (2013) The spectrum of type I cryoglobulinemia vasculitis: new insights based on 64 cases. Med (Baltim) 92(2):61\u201368","journal-title":"Med (Baltim)"},{"issue":"13","key":"5712_CR38","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1182\/blood-2018-06-846816","volume":"132","author":"MA Gertz","year":"2018","unstructured":"Gertz MA (2018) Acute hyperviscosity: syndromes and management. Blood 132(13):1379\u20131385","journal-title":"Blood"},{"issue":"2","key":"5712_CR39","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/jca.22043","volume":"38","author":"L Connelly-Smith","year":"2023","unstructured":"Connelly-Smith L, Alquist CR, Aqui NA, Hofmann JC, Klingel R, Onwuemene OA et al (2023) Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based Approach from the Writing Committee of the American Society for Apheresis: the Ninth Special Issue. J Clin Apher 38(2):77\u2013278","journal-title":"J Clin Apher"},{"issue":"2","key":"5712_CR40","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/ajh.26796","volume":"98","author":"MA Gertz","year":"2023","unstructured":"Gertz MA, Waldenstr\u00f6m macroglobulinemia (2023) 2023 update on diagnosis, risk stratification, and management. Am J Hematol 98(2):348\u2013358","journal-title":"Am J Hematol"},{"issue":"1","key":"5712_CR41","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jca.21257","volume":"28","author":"AA Kaplan","year":"2013","unstructured":"Kaplan AA (2013) Therapeutic plasma exchange: a technical and operational review. J Clin Apher 28(1):3\u201310","journal-title":"J Clin Apher"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05712-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05712-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05712-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T09:07:27Z","timestamp":1729933647000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05712-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,1]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["5712"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05712-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,1]]},"assertion":[{"value":"28 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jack Khouri: Consultancy for Janssen.The rest of the authors have no financial or non-financial potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}